Value proposition

Harnessing the microbiome for the development of diagnosis and therapeutic tools in cancer !

EverImmune is a biotechnology company specialized in the development of live biotherapeutic products in the field of microbiota oncology.

It harnesses the gut microbiota for the development of a unique approach aiming to restore the response of Immune Checkpoint Inhibitors (ICIs) in cancer patients.

The company is developing Oncobax AK, a Live Biotherapeutic Product (LBP) used as an oral adjuvant to anticancer immunotherapies, designed to safely boost the immune system and restore sensitivity to immunotherapies in primary resistance settings. The company also develops other bacteria in its pipeline for use in the treatment of different types of cancer.

Established in 2016, by co-founders Pr. Laurence Zitvogel and Dr. Romain Daillere, everImmune is a spinoff from Gustave Roussy (Paris, France). The company is part of ONCOBIOME, the first European program dedicated to microbiome and cancer, funded by the European Union.